ActiveMSers Forums  

Go Back   ActiveMSers Forums > Forums > General

Thread Tools Display Modes
Old 05-07-2019, 05:40 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 4,065

More on the topic from the 2019 AAN conference... It's waaay common. -D

Sexual Dysfunction in Multiple Sclerosis: A Systematic Review and Meta-Analysis of

David Kim, et al

To perform a systematic review and meta-analysis to estimate the point prevalence of sexual dysfunction (SD) in multiple sclerosis (MS) patients, total and stratified by gender.

Although SD is commonly observed in MS patients, it is frequently overlooked in the clinical setting. There remains limited consensus on the actual prevalence and determinants of SD in patients with MS.

Relevant literature databases were searched for studies reporting on the prevalence of SD in MS between January 1977 and January 2015. Random-effects models were used to pool reported prevalence of SD in MS. Stratified meta-analysis and meta-regression were used to estimate differences due to study-level characteristics. Heterogeneity was assessed using DerSimonian and Lairdís Q-test and the I2-index. Sensitivity analyses were performed to assess studies deemed to have low risk-of-bias (ROB) according to a modified version of the Newcastle-Ottawa Scale.

6135 studies were retrieved, of which 43 met inclusion and exclusion criteria. The overall pooled weighted prevalence of SD was 58% (6635/14538 individuals, 95% CI, 52-64%), 63% in women (95% CI, 53-74%; n=27 studies), and 62% in men (95% CI, 54-69%; n=24 studies). There was significant between-study heterogeneity (all MS: Q= 1608.63, I2 = 97.39%; women: Q= 1608.63, I2 = 97.39%; men: Q=302.34, I2 = 92.39%, p<0.01 for all). Pooled meta-regression did not indicate a significant association of SD prevalence with age, disability (Expanded Disability Status Scale), duration of disease, or proportion with relapsing-remitting disease. A sensitivity analysis including only studies deemed to have low ROB did not result in a significant difference in the pooled prevalence of SD (55%, 95% CI, 48-62%, p=0.95).

SD is highly prevalent in MS patients, across the spectrum of disease. These data highlight the need for increased recognition of SD within MS clinical practice and evidence-based approaches to address this facet of
the disease.
Dave Bexfield
Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

All times are GMT -4. The time now is 07:53 PM.

Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.